PE20221465A1 - Anticuerpos anti-trem2 y metodos para utilizarlos - Google Patents

Anticuerpos anti-trem2 y metodos para utilizarlos

Info

Publication number
PE20221465A1
PE20221465A1 PE2022001437A PE2022001437A PE20221465A1 PE 20221465 A1 PE20221465 A1 PE 20221465A1 PE 2022001437 A PE2022001437 A PE 2022001437A PE 2022001437 A PE2022001437 A PE 2022001437A PE 20221465 A1 PE20221465 A1 PE 20221465A1
Authority
PE
Peru
Prior art keywords
trem2
methods
antibody
polypeptide
trem2 antibodies
Prior art date
Application number
PE2022001437A
Other languages
English (en)
Spanish (es)
Inventor
Mark S Dennis
Zhenyu Gu
Mihalis S Kariolis
Cathal S Mahon
Kathryn M Monroe
Joshua I Park
Rachel Prorok
Adam P Silverman
Lengerich Bettina Van
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of PE20221465A1 publication Critical patent/PE20221465A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PE2022001437A 2020-01-13 2021-01-13 Anticuerpos anti-trem2 y metodos para utilizarlos PE20221465A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202062960663P 2020-01-13 2020-01-13
US202063070728P 2020-08-26 2020-08-26
US202063091717P 2020-10-14 2020-10-14
PCT/US2021/013200 WO2021146256A1 (en) 2020-01-13 2021-01-13 Anti-trem2 antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
PE20221465A1 true PE20221465A1 (es) 2022-09-21

Family

ID=74587108

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022001437A PE20221465A1 (es) 2020-01-13 2021-01-13 Anticuerpos anti-trem2 y metodos para utilizarlos

Country Status (17)

Country Link
US (1) US20220177576A1 (cg-RX-API-DMAC7.html)
EP (1) EP4090682A1 (cg-RX-API-DMAC7.html)
JP (1) JP7870250B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220131246A (cg-RX-API-DMAC7.html)
CN (1) CN115279790A (cg-RX-API-DMAC7.html)
AU (1) AU2021208482B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022013756A2 (cg-RX-API-DMAC7.html)
CA (1) CA3166385A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022001886A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022009744A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22054464A (cg-RX-API-DMAC7.html)
IL (1) IL294655A (cg-RX-API-DMAC7.html)
MX (1) MX2022008582A (cg-RX-API-DMAC7.html)
PE (1) PE20221465A1 (cg-RX-API-DMAC7.html)
PH (1) PH12022551650A1 (cg-RX-API-DMAC7.html)
TW (1) TWI890727B (cg-RX-API-DMAC7.html)
WO (1) WO2021146256A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
BR112020005271A2 (pt) 2017-10-02 2020-09-15 Denali Therapeutics Inc. proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
JP7543290B2 (ja) 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
BR112022012230A2 (pt) 2019-12-23 2022-08-30 Denali Therapeutics Inc Variantes de progranulina
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
IL311003A (en) 2021-08-25 2024-04-01 Denali Therapeutics Inc Anti-2HER antibodies and methods of using them
MX2024010324A (es) 2022-02-23 2024-08-30 Alector Llc Metodos de uso de anticuerpos anti-trem2.
EP4499693A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
EP4499695A1 (en) 2022-03-28 2025-02-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2024253424A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간화 항체 및 이의 용도
WO2024253420A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2026062582A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies
WO2026062585A1 (en) * 2024-09-20 2026-03-26 Novartis Ag Methods of treatment using anti-trem2 antibodies

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
EA201790342A1 (ru) * 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
JP7725185B2 (ja) * 2015-10-06 2025-08-19 アレクトル エルエルシー 抗trem2抗体及びその使用方法
RS63818B1 (sr) 2017-02-17 2023-01-31 Denali Therapeutics Inc Konstruisani polipeptidi za vezivanje za receptor transferina
EP4628586A3 (en) 2017-02-17 2026-01-14 Denali Therapeutics Inc. Transferrin receptor transgenic models
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
HUE062436T2 (hu) 2017-08-03 2023-11-28 Alector Llc Anti-trem2 antitestek és alkalmazási módszereik
WO2019055841A1 (en) * 2017-09-14 2019-03-21 Denali Therapeutics Inc. ANTI-TREM2 ANTIBODIES AND METHODS OF USE
CN113302206A (zh) 2018-11-26 2021-08-24 戴纳立制药公司 治疗脂质代谢失调的方法
JP7543290B2 (ja) * 2019-02-20 2024-09-02 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法

Also Published As

Publication number Publication date
EP4090682A1 (en) 2022-11-23
KR20220131246A (ko) 2022-09-27
MX2022008582A (es) 2022-08-10
US20220177576A1 (en) 2022-06-09
CN115279790A (zh) 2022-11-01
PH12022551650A1 (en) 2024-02-12
JP7870250B2 (ja) 2026-06-04
BR112022013756A2 (pt) 2022-10-11
WO2021146256A1 (en) 2021-07-22
TWI890727B (zh) 2025-07-21
CO2022009744A2 (es) 2022-07-19
CL2022001886A1 (es) 2023-03-24
JP2023512450A (ja) 2023-03-27
ECSP22054464A (es) 2022-08-31
AU2021208482A1 (en) 2022-07-21
AU2021208482B2 (en) 2025-12-11
TW202128771A (zh) 2021-08-01
CA3166385A1 (en) 2021-07-22
IL294655A (en) 2022-09-01

Similar Documents

Publication Publication Date Title
CO2021006248A2 (es) Anticuerpos anti-nkg2a y usos de los mismos
PE20211767A1 (es) Anticuerpos anti-hla-g, composiciones que comprenden anticuerpos anti-hla-g y metodos de uso de anticuerpos anti-hla-g
EA202092460A1 (ru) Антитела к ox40 и способы применения
PE20210377A1 (es) Anticuerpos anti-pd-l1 y usos de los mismos
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
ECSP21010450A (es) Anticuerpos anti–sortilina y métodos para su uso
JP2018512379A5 (cg-RX-API-DMAC7.html)
PE20090329A1 (es) Anticuerpos humanizados contra el globulomero ab(20-42) y sus usos
PE20140448A1 (es) Moleculas de union biespecificas que se unen a vegf y ang2
HRP20240719T1 (hr) Kimerna i humanizirana monoklonska protutijela protiv ljudskog ctla4 i njihova upotreba
CO6251370A2 (es) Una molecula de union cd20 humanizda que comprende un dominio variable de cadena pesada de inmunoglobulina (vh) y un dominio variable de cadena liviana de inmunoglobulina (vl) y metodos de uso de la misma
PE20221449A1 (es) Agentes de union a cd8 y usos de los mismos
HRP20191095T1 (hr) Humanizirano anti kallikrein-2 antitijelo
PE20221256A1 (es) Anticuerpos dirigidos a flt3 y uso de los mismos
PE20230444A1 (es) Anticuerpos
AR079458A2 (es) Anticuerpo monoclonal quimerico que se une a cd45
EA202092420A1 (ru) Антитело против pd-l1 и его применение
MX2020006155A (es) Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
CR20190525A (es) Proteínas de unión a antígenos trem2 y usos
CO6260104A2 (es) Anticuerpos contra la il-25
MX2021015212A (es) Anticuerpos antisortilina para uso en terapia.
PE20240895A1 (es) Anticuerpos del receptor antitransferrina y usos de los mismos
EA202190183A1 (ru) Антитела к siglec-5 и способы их применения
MX2024010324A (es) Metodos de uso de anticuerpos anti-trem2.
EA202092595A1 (ru) Антитела к siglec-7 и способы их применения